España
India
Italia
대한민êµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Belite Bio
BLTE
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$56.21
3.17
5.98%
At close: -
$53.55
-2.66
-4.73%
After Hours: Jan 15, 7:57 AM EDT
Get Report
Comment
Belite Bio (BLTE) Forecast
News
Earnings
Belite Bio (BLTE) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Belite Bio (NASDAQ:BLTE) Stock
Belite Bio Stock (NASDAQ: BLTE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 27, 2024
Belite Bio shares are trading higher after th...
Benzinga Newsdesk
Lin BioScience's LBS-007 Granted FDA Fast Tra...
Benzinga Newsdesk
Friday, November 15, 2024
Maxim Group Maintains Buy on Belite Bio, Rais...
Benzinga Newsdesk
Wednesday, November 13, 2024
HC Wainwright & Co. Maintains Buy on Belite B...
Benzinga Newsdesk
Tuesday, November 12, 2024
Earnings Scheduled For November 12, 2024
Benzinga Insights
Belite Bio Q3 2024 GAAP EPS $(0.28) Beats $(0...
Benzinga Newsdesk
Monday, November 11, 2024
Insights into Belite Bio's Upcoming Earnings
Benzinga Insights
Thursday, September 12, 2024
HC Wainwright & Co. Reiterates Buy on Belite ...
Benzinga Newsdesk
Tuesday, September 10, 2024
Belite Bio Doses First Patient In Phase 2/3 D...
Benzinga Newsdesk
Tuesday, September 03, 2024
Reported Earlier, Belite Bio Taps Hendrik P. ...
Benzinga Newsdesk
Tuesday, August 13, 2024
HC Wainwright & Co. Maintains Buy on Belite B...
Benzinga Newsdesk
Benchmark Reiterates Buy on Belite Bio, Maint...
Benzinga Newsdesk
Friday, August 09, 2024
Belite Bio Q2 2024 GAAP EPS $(0.26) Misses $(...
Benzinga Newsdesk
Thursday, June 20, 2024
Cantor Fitzgerald Reiterates Overweight on Be...
Benzinga Newsdesk
Thursday, June 13, 2024
HC Wainwright & Co. Reiterates Buy on Belite ...
Benzinga Newsdesk
Wednesday, June 12, 2024
Belite Bio Announces That Its Lead Pipeline, ...
Benzinga Newsdesk
Thursday, May 16, 2024
Benchmark Reiterates Buy on Belite Bio, Maint...
Benzinga Newsdesk
Wednesday, May 15, 2024
HC Wainwright & Co. Reiterates Buy on Belite ...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on Be...
Benzinga Newsdesk
Tuesday, May 14, 2024
Belite Bio Q1 2024 GAAP EPS $(0.27) Beats $(0...
Benzinga Newsdesk
Monday, May 06, 2024
Belite Bio Presents Additional Analysis From ...
Benzinga Newsdesk
Friday, April 26, 2024
Reported Earlier, Belite Bio Secures $25M In ...
Benzinga Newsdesk
Friday, March 22, 2024
HC Wainwright & Co. Maintains Buy on Belite B...
Benzinga Newsdesk
Belite Bio Announces PMDA Submission of Tinla...
Benzinga Newsdesk
Wednesday, March 13, 2024
HC Wainwright & Co. Reiterates Buy on Belite ...
Benzinga Newsdesk
Tuesday, March 12, 2024
Belite Bio Q4 EPS $(0.25) Beats $(0.30) Estim...
Benzinga Newsdesk
Wednesday, December 27, 2023
HC Wainwright & Co. Reiterates Buy on Belite ...
Benzinga Newsdesk
Thursday, December 14, 2023
Expert Ratings for Belite Bio
Benzinga Insights
Maxim Group Initiates Coverage On Belite Bio ...
Benzinga Newsdesk
Sunday, December 10, 2023
Belite Bio Received Approval To Initiate Tinlarebant Phase 3 Clinical Trial For GA in Switzerland
Charles Gross
Wednesday, November 15, 2023
HC Wainwright & Co. Reiterates Buy on Belite ...
Benzinga Newsdesk
Tuesday, November 14, 2023
Earnings Scheduled For November 14, 2023
Benzinga Insights
Belite Bio Q3 EPS $(0.40) Down From $(0.10) Y...
Benzinga Newsdesk
Tuesday, November 07, 2023
Benchmark Reiterates Buy on Belite Bio, Maint...
Benzinga Newsdesk
Monday, November 06, 2023
HC Wainwright & Co. Maintains Buy on Belite B...
Benzinga Newsdesk
Belite Bio Presented Final Data From A 24-mon...
Benzinga Newsdesk
Tuesday, October 17, 2023
Belite Bio Announces NMPA Submission For Tinl...
Benzinga Newsdesk
Wednesday, August 30, 2023
Belite Bio shares are trading lower. Not seei...
Benzinga Newsdesk
Monday, August 14, 2023
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
Thursday, August 10, 2023
Expert Ratings for Belite Bio
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Belite ...
Benzinga Newsdesk
Wednesday, August 09, 2023
Earnings Scheduled For August 9, 2023
Benzinga Insights
Belite Bio Q2 EPS $(0.26) Down From $(0.12) Y...
Benzinga Newsdesk
Friday, August 04, 2023
Belite Bio Receives Approval To Initiate Tinl...
Benzinga Newsdesk
Friday, July 28, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023
Benzinga Insights
Cantor Fitzgerald Initiates Coverage On Belit...
Benzinga Newsdesk
Thursday, July 27, 2023
Belite Bio Doses First Subject In Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant For Geographic Atrophy
Happy Mohamed
Wednesday, July 26, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
Benzinga Insights
SVB Leerink Initiates Coverage On Belite Bio ...
Benzinga Newsdesk
Tuesday, July 25, 2023
The Latest Analyst Ratings for Belite Bio
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
